enalapril matching placebo

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Acute Heart FailureErectile DysfunctionHeart FailureHeart Failure, Systolic

Phase 3

COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure

CompletedNCT03917459

Novartis PharmaceuticalsErectile Dysfunction, Heart Failure, Heart Failure, Systolic

Start: 2019-04-16End: 2021-05-25Updated: 2024-02-29

Phase 4

Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.

CompletedNCT02554890

Novartis PharmaceuticalsAcute Heart Failure

Start: 2016-04-29End: 2018-07-24Updated: 2021-01-05

Related Papers

Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure

Journal of the American College of Cardiology2024-03-0121 citations

Angiotensin-Neprilysin Inhibition in Black Americans

JACC Heart Failure2020-09-0918 citations

Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists.

2020-09-0141 citations

Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial

JACC Heart Failure2020-08-1236 citations

Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan.

2020-01-1613 citations

Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure

JAMA Cardiology2019-12-1186 citations

Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial.

2019-10-0149 citations

Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure

New England Journal of Medicine2018-11-111207 citations